FDA Extends Review Period of Sanofi's Multiple Sclerosis Drug Filing

Sanofi's FDA target action date for its Bruton's tyrosine kinase (BTK) inhibitor, tolebrutinib, for non-relapsing, secondary progressive multiple sclerosis (nrSPMS) has been extended by three months to December 28, 2025. This delay stems from Sanofi's submission of new analyses, which the FDA deemed a major amendment to the New Drug Application. While the drug holds Breakthrough Therapy designation and could address a significant unmet need as the first approved therapy for nrSPMS, this extension, following a prior partial clinical hold in 2022 due to liver injury concerns, introduces further uncertainty into its market entry timeline and potential impact on Sanofi's pipeline value.

Analysis

The U.S. FDA has extended its review period for Sanofi's (SNY) New Drug Application for tolebrutinib by three months, pushing the target action date to December 28, 2025. This delay was prompted by Sanofi's submission of additional analyses, which the agency deemed a "major amendment" to the application. While the drug, a BTK inhibitor for non-relapsing secondary progressive multiple sclerosis (nrSPMS), is under Priority Review and holds Breakthrough Therapy designation, this timeline extension introduces uncertainty. Tolebrutinib aims to address a significant unmet need, as there are currently no approved therapies for nrSPMS. However, this regulatory delay must be viewed in the context of a partial clinical hold placed by the FDA in 2022 due to identified cases of drug-induced liver injury, which adds a layer of risk to the final approval decision. The stock's performance reflects this uncertainty, with shares having lost 2.5% year-to-date against the industry's 0.9% growth. Upcoming catalysts, including a regulatory decision in the EU and data from another Phase III study by the end of 2025, will be critical in shaping the asset's future.

Key Decisions for Investors

• The three-month delay in the tolebrutinib decision pushes back the potential revenue timeline for a key pipeline asset, creating a near-term valuation overhang for Sanofi.
• Investors should closely monitor the nature of the FDA's inquiries regarding the 'major amendment' for any connection to the prior safety signal of drug-induced liver injury, which remains the primary risk for the program.
• Key inflection points to watch for are the parallel regulatory decision in the EU and data from the PERSEUS study in late 2025, which could either de-risk the asset or amplify existing concerns.
• Given Sanofi's 2.5% year-to-date share price decline, which underperforms the industry, this extended regulatory uncertainty could present further headwinds until a clear path to approval is established.